•  

     

    NEWS

    The most relevant news about our Group, in Argentina and around the world.

Exeltis, more leader than ever in Spain

This is Exeltis from the Insud Group which recently acquired the Juste Farma division of the Juste laboratory in Spain. This long-standing company is dedicated to the sale of pharmaceutical products of gynecology, central nervous system and primary care.

Beyond the fact that Exeltis is already installed in Spain, the recent incorporation achieves a better positioning and allows the purchase of medicines for the treatment of several pathologies of high prevalence such as: insomnia, depression and epilepsy, among others. This development also includes research, promotion and marketing activities as well as its sales network.

The laboratory Juste, has an extensive experience, having been part of the Spanish market since 1922. Over the years they developed ophthalmological products, specialized in contrast for radiological studies, until the development of extensive lines of treatment. It currently has a production plant that leads in competitiveness.

Exeltis is part of Grupo Insud, a business conglomerate dedicated to the pharmaceutical, agroforestry, cultural and nature and design industries. Silvia Gold and Hugo Sigman, founders and shareholders, started in the pharmaceutical industry in 1977 and today the group has a presence in more than 40 countries forming a group of national capitals.

The incorporation of this company supposes the increase of approximately 300 products oriented mainly the health of the woman and the primary attention.

(Español) Ver nota completa

Top Story

News

Algunas aclaraciones sobre la vacuna | Hugo Sigman

Por Hugo Sigman En momentos en que la segunda ola de Covid se cobra más y más muertos, con muchas familias perdiendo a sus seres queridos y el sistema de salud muy estresado, la intoxicación de noticias falsas sólo contribuye … Continue reading

+

Latest News

News Mabxience

Hugo Sigman, sobre la vacuna de AstraZeneca: “Confiamos en que las pruebas serán exitosas”

+

News Grupo Insud Mundo Sano

El futuro de la pandemia visto por la bioquímica Silvia Gold: “Mucho de lo que aprendimos con dengue, creemos que es lo que hay que hacer con COVID-19″

+

News Grupo Insud

Hugo Sigman: “El único negocio que tengo con el Estado representa el 1,5% de mi facturación”

+

News Top Story Grupo Insud

Silvia Gold: “Las vacunas que más esperanza nos generan son las de vector viral”

+

News Top Story Mabxience

mAbxience: cómo es el laboratorio argentino que va a producir la vacuna de la Universidad de Oxford y AstraZeneca para América Latina

+

News Inmunova Top Story

ANMAT aprobó estudio clínico en humanos para el suero anti-Covid-19

+

News Grupo Insud

Startups con participación del CONICET se presentarán en BioArgentina 2021

+

News Grupo Insud

La OPS selecciona centros en Argentina y Brasil para desarrollar vacunas de ARNm contra la COVID-19

+